Image Image Image Image Image Image Image Image Image Image
Доступ
Идти наверх

Идти наверх

FOVISTA: Clinical Trial for subfoveal neovascular age-related macular degeneration
19/03/2014

Foto2

 

Description 

A phase 3 Randomized, doubled masked, controlled trial to establish the safety and efficacy of intravitreous administration of FOVISTA (anti-PDGF-b pegylated aptamer) administered in combination with Lucentis compared to Lucentis Monotherpahy in subjects with subfoveal neovascular age-related macular degeneration.

Objectives

The objectives of the study are to evaluate the safety and efficacy of FOVISTA in combination with ranibizumab (Lucentis) as compared to ranibizumab monotherapy in patients with neovascular age-related macular degeneration who have not received previous treatment.

5471__MG_8270red (1)


If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155. 

Our team of professionals will answer you as soon as possible and we will assess whether you are eligible. 

 

 

Интравитреальные инъекцииЭкссудативная или влажная ВМД

Author

Доктор Jordi Monés, M.D., Ph.D.
Номер лицензии COMB: 22.838
Директор
Доктор Медицины и Хирургии
Специалист по Офтальмологии
Специалист по лечению Сетчатки, Макулы и Стекловидного тела

Last modified: 17 July, 2019 - 14:57